Brief: China NT Pharma Group Says Unit's Drug Shusi Got Approval In Consistency Evaluation
20/02/2020 12:10
Feb 20 (Reuters) - China NT Pharma Group Company Ltd
1011.HK :
* SHUSI, A COMPOUND MEDICINE OF UNIT SUZHOU FIRST
PHARMACEUTICAL,
APPROVED IN CONSISTENCY EVALUATION OF CHINA FDA
* SHUSI IS USED TO TREAT BIPOLAR AFFECTIVE DISORDER; PASSED
HEAD-TO-HEAD COMPARISON CLINICAL TRIALS WITH ORIGINAL DRUG
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2hmHqV
Further company coverage: 1011.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY